Jourdeness Group Ltd. AI Stock Analysis
Jourdeness Group Ltd. (4190) AI Stock Analysis
Jourdeness Group Ltd.
(TWSE:4190)
The overall score is critically low, driven primarily by severe fundamental and technical weaknesses. The company is unprofitable with a highly leveraged balance sheet, and the stock is in a strong downtrend with deeply oversold momentum. The modestly positive cash flow generation is the only mitigating factor, but it is insufficient to offset the significant risks from persistent net losses and high debt.
Jourdeness Group Ltd. (4190) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.31B
- Dividend Yield
- 2.24%
- Average Volume (3M)
- 20.18K
- Price to Earnings (P/E)
- -14.1
- Beta (1Y)
- 0.40
- Revenue Growth
- -1.05%
- EPS Growth
- 34.07%
- Country
- TW
- Employees
- 6,108
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
Jourdeness Group Ltd. Business Overview & Revenue Model
Company Description
Jourdeness Group Limited, together with its subsidiaries, manufactures and sells cosmetics in China, Taiwan, and internationally. The company also engages in the beauty and body spa business; and operation of a tourist factory, as well as offers cons...
Jourdeness Group Ltd. Financial Statement Overview
Summary
Financial performance is deeply strained. While cash flow is positive and improving, the income statement shows a net loss with a -1.6% EBIT margin, and the balance sheet is highly leveraged with a debt-to-equity ratio of 1.72 and negative shareholder returns. The divergence between cash generation and accrual profitability is a major concern.
Income Statement
28NegativeBalance Sheet
35NegativeCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.26B | 2.31B | 2.28B | 2.98B | 2.78B | 2.82B |
| Gross Profit | 1.32B | 1.48B | 1.40B | 2.01B | 1.89B | 2.06B |
| EBITDA | 417.11M | 615.39M | 535.32M | 878.66M | 802.49M | 1.14B |
| Net Income | -83.95M | -94.26M | -291.95M | -258.00K | 13.98M | 292.16M |
Balance Sheet | ||||||
| Total Assets | 7.25B | 6.79B | 7.39B | 7.86B | 8.05B | 8.44B |
| Cash, Cash Equivalents and Short-Term Investments | 1.77B | 1.16B | 1.15B | 1.33B | 1.37B | 2.44B |
| Total Debt | 3.33B | 2.82B | 3.03B | 3.01B | 3.00B | 3.51B |
| Total Liabilities | 5.63B | 5.16B | 5.62B | 5.78B | 5.89B | 6.16B |
| Stockholders Equity | 1.61B | 1.64B | 1.77B | 2.08B | 2.16B | 2.28B |
Cash Flow | ||||||
| Free Cash Flow | 437.97M | 426.82M | 256.20M | 339.17M | -40.59M | 354.33M |
| Operating Cash Flow | 509.89M | 511.35M | 416.51M | 715.79M | 747.12M | 985.77M |
| Investing Cash Flow | -111.70M | -235.93M | -36.49M | -1.09B | -532.66M | -875.22M |
| Financing Cash Flow | 174.12M | -404.07M | -356.40M | -367.71M | -1.05B | 801.72M |
Jourdeness Group Ltd. Peers Comparison
Overall Rating
TW:316471Outperform
TW:684655Neutral
TW:180544Neutral
TW:657842Neutral- TW:419038Underperform
TW:643138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:3164 | 71Outperform | TWD 1.44B | 23.61 | ― | 4.71% | 1.32% | 80.16% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6846 | 55Neutral | TWD 1.37B | 12.95 | ― | 7.81% | -3.09% | -27.23% |
| TW:1805 | 44Neutral | TWD 1.31B | 71.46 | ― | ― | -59.33% | -94.38% |
| TW:6578 | 42Neutral | TWD 1.21B | -49.87 | ― | 2.35% | 21.50% | -5.51% |
| TW:4190 | 38Underperform | TWD 1.31B | -14.14 | ― | 2.24% | -1.05% | 34.07% |
| TW:6431 | 38Underperform | TWD 1.42B | -7.70 | ― | ― | 11.20% | 21.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4190 | Jourdeness Group Ltd. | 22.35 | -8.58 | -27.74% | |
| TW:1805 | Better Life Group Co., Ltd. | 9.74 | -2.51 | -20.49% | |
| TW:3164 | GenMont Biotech, Inc. | 17.00 | -0.71 | -4.00% | |
| TW:6431 | Kuangli Bio-Tech Holdings Co., Ltd. | 15.25 | -1.00 | -6.15% | |
| TW:6578 | Dabomb Protein Biotech Corporation | 16.70 | -2.95 | -15.01% | |
| TW:6846 | Greenyn Biotechnology Co., Ltd. | 50.50 | -22.25 | -30.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026